Quarterly / Interim Statement/9 Month figuresDermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time 14.11.2024 / 07:30 ...
Dermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time Consolidated revenue up 2.7% to EUR 890.1 million. Growth in high-margin ...
This facility will be replaced by the new revolving credit facilities that are expected to be finalized subsequent to the interim financial reporting date (see note 6.4). 6. CONVERTIBLE NOTES AND LOAN ...
Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...